Status:
UNKNOWN
Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Tranexamic Acid
Intraoperative Blood Loss
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Intra-operative blood loss of huge meningioma resection patients on average was over 1000ml. Intra-operative massive hemorrhage was associated with longer hospital of stay, higher expense, and higher ...
Eligibility Criteria
Inclusion
- Patients undergoing elective supratentorial meningioma resection with estimated tumor diameter \>5cm on brain image.
- Age between 18-65 years.
- American Society of Anaesthesiologist (ASA) physical status Ⅰ to Ⅲ
- Obtain written informed consent.
Exclusion
- Allergic to tranexamic acid.
- History of thrombotic disease.
- History of chronic kidney disease
- Receiving other anticoagulation or antiplatelet treatment.
- Refuse to provide written informed consent
Key Trial Info
Start Date :
June 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
228 Patients enrolled
Trial Details
Trial ID
NCT05230381
Start Date
June 15 2022
End Date
June 30 2025
Last Update
August 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100070